HOME ZACKS RESEARCH FUNDS PORTFOLIO BROKER RESEARCH MARKETS SCREENING EDUCATION SERVICES
Earnings    EPS Surprises    Mutual Funds    Options    My Account    Help    

Zacks #1 Rank
See how a purely mathematical analysis of earnings estimate revisions returns over 27% per year on average. Click Here to Learn More.
Quote:
Login Free Membership
Search:

Top Zacks Features
Free Membership
Premium Home
Zacks Rank
Equity Research
My Portfolio
Stock Screener
Profit Tracks
Mutual Funds
Options
Zacks Video
RSS Feed
Profit from the Pros

Subscription Services
Product Guide
Zacks Premium
Zacks Elite
Method for Trading
Chart Patterns Trader
Double Your Money
ETF Trader
Growth Trader
Options Trader
Small Cap Trader
Strategic Investor
Surprise Trader
Top 10 Stocks
Value Trader
Special Reports
Research Wizard

Zacks Premium
Get profitable stock
picks and timely
market advice in
Zacks.com`s Free
Daily Newsletter!

Free Registration

View the Archive


MDVN: Medivation Inc - Stock News Enter Ticker:
 

QuoteEstimatesCharts Company ReportsNewsFinancials
  Company News |  Zacks Commentary
MEDIVATION INC (NASD)
MDVN 29.22 0.59 (2.06%) Vol.  597,737 16.00 CST

Nov 19, 2009 MDVN Starts New Alzheimer's Trials
Nov 11, 2009 Medivation to Present at Lazard Capital Markets Sixth Annual Healthcare Conference
Nov 06, 2009 Medivation Lags Expectations
Nov 04, 2009 Medivation Reports Third Quarter 2009 Financial Results and Provides Corporate Update
Nov 04, 2009 Conference Calls Today: 4:30 P.M. EDT
Oct 28, 2009 JAPAN'S ASTELLAS BUYS DEV'T,SALES RIGHTS TO PROSTATE CANCER DRUG
Oct 28, 2009 MONSTERSTOX.COM: Monsterstox.com : Medivation, Inc. (Nasdaq: MDVN)
Oct 28, 2009 Medivation Announces Third Quarter 2009 Financial Results Teleconference and Webcast on November 4, 2009
Oct 27, 2009 MDVN: CEO Comments Today on Agreement w/Astellas Pharma for MDV3100
Oct 27, 2009 MONSTERSTOX.COM: Monsterstox.com : Medivation, Inc. (Nasdaq: MDVN)
Oct 27, 2009 MDVN: Development and Commercialization Agreement w/Astellas for MDV3100
Oct 27, 2009 MDVN: Conference call regarding Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer @ 08:30 ET Today [delayed]
Oct 27, 2009 Astellas and Medivation Enter Into Worldwide Agreement to Co-Develop and Co-Commercialize MDV3100 for the Treatment of Prostate Cancer
Oct 26, 2009 Medivation to Host Conference Call at 8:30 a.m. Eastern Time Tomorrow to Discuss Partnering Plans for MDV3100
Oct 23, 2009 Medivation Names Hank Mansbach, M.D., Vice President of Medical Affairs
 
ZACKS COMMENTARY FOR MDVN
Nov 18, 2009 Zacks Blog: MDVN Starts New Alzheimer’s Trials
Nov 13, 2009 Zacks Equity Research: Report for MDVN
Nov 06, 2009 Zacks Blog: Medivation Lags Expectations
Jun 30, 2009 Zacks Blog: Zacks Analyst Blog Highlights: Hasbro, Mattel, Medivation Inc., Pfizer and Raser Technologies
Jun 29, 2009 Zacks Blog: Medivation - Dimebon Launch in 2012?
May 15, 2009 Zacks Blog: Drug Cos to Present at ASCO
May 13, 2009 Zacks Blog: Medivation Drugs a Ways Off
Feb 19, 2009 Zacks Blog: Zacks.com featured expert Kevin Matras highlights: AeroVironment, Inc., Capella Education Company, BJ’s Restaurants, Inc., Green Mountain Coffee Roasters, Inc....
Feb 17, 2009 Screen of the Week: Using Moving Averages to Find Winning Stocks

 
About Zacks | Advertise | Media | Careers | Contact Us | Help
Disclaimer | Privacy Policy | Sitemap
NYSE and AMEX data is at least 20 minutes delayed.  NASDAQ data is at least 15 minutes delayed.
Copyright 2009 Zacks Investment Research